Skip to content
printicon
Main menu hidden.
Published: 2022-11-17 Updated: 2022-11-18, 08:27

Recent infection research at MIMS and Baltic collaborations in focus

NEWS MIMS welcomed its Executive Board and research community to the MIMS Symposium 11 November to share significant advances in research and its growing Baltic collaborations.

Text: Gretchen Repasky and Nóra Lehotai

It was an impressive seminar with high-quality research presented and excitement in the room, emanating especially from the young community. 

“I am pleased that we could bring the community of infection researchers and microbiologists together locally, in the spirit of having scientific exchange, and exploring collaborative opportunities, at the same time as we have the members of the MIMS Executive Board here”, says Professor Oliver Billker, MIMS Director of Molecular Infection Medicine Sweden at Umeå University.

The MIMS Symposium 11 December in Aula Biologica at Umeå Unievrsity highlighted MIMS research and Baltic collaborations for the local scientific community and the visiting MIMS Executive Board.

Recent advances in MIMS research

In the first half of the symposium, leading scientists affiliated with MIMS presented significant, recent advances. Dr. Anne-Marie Fors Connolly, MIMS Clinical Research Fellow, demonstrated the power of Swedish and Nordic registry data to better understand cardiovascular disease risk related to SARS-CoV-2 infection.

Dr. André Mateus, MIMS Team Leader, shared systems biology approaches to mapping bacterial protein function and characterizing functional units in cells. Furthermore, using advanced electron tomography techniques, Dr. Lars-Anders Carlson, MIMS Investigator, showed how viruses rearrange the host cellular interior.

“It was an impressive seminar with high-quality research presented and excitement in the room, emanating especially from the young community. There were lots of interactions and great hope for the future. The topics that were highlighted showed different aspects of infection biology research tackling challenges like antibiotic resistance and COVID-19”, says Professor Gunilla Westergren-Thorsson, MIMS Executive Board member, Lund University.

With these different areas MIMS maintains close ties with clinicians, researchers driving local infrastructure, and pioneering fellows of other national programmes, all helping to translate basic research into powerful applied tools in medicine.

Joint research with Baltic countries

In the second half of the symposium the audience travelled in their minds along the Baltic Sea to the universities in Vilnius and Tartu and learned about existing joint research initiatives and opportunities for new collaborations.

Professor Virginijus Šikšnys, Head of Vilnius University Life Science Center EMBL Partnership Institute, introduced the EMBL Partnership and presented key discoveries in genome editing technologies coming out of Vilnius. VU-LSC Group Leader

Dr. Stephen Knox Jones, Group Leader, EMBL Partnership Institute at Vilnius University Life Science Center, piqued curiosity through interdisciplinary approaches - infection biology and tools for genome editing. With continually expanding possibilities that CRISPR-Cas systems provide, MIMS scientists look forward to collaborations with the Lithuanian EMBL Partnership.

“Some say that what you do not know cannot hurt you. But I was thinking of the other side of that, which this meeting is a good example of: ‘what you do not know cannot help you’.  A lot of times people focus only on conferences or meetings where they have a clear, specific topic that they want to know or learn about, but I would argue that it actually is the exposure to different topics where the cool stuff comes from”, says Dr. Stephen Knox Jones.

Professor Tanel Tenson closed the symposium with a discussion on bacterial phenotypic heterogeneity and antibiotic tolerance. As one of the drivers of the MIBest EU Horizon 2020 project, he also emphasized essential collaborations with numerous MIMS group leaders and senior PIs. The MIBest project strengthens research capacity in infection biology at the University of Tartu by linking Tartu to two leading institutes in the field: Basel Biozentrum in Switzerland and MIMS in Sweden.

Overall, the event boosted long-overdue, face-to-face interactions with collaborators from the Baltic region, propelled new opportunities, and generated a special excitement for the local scientific community.

The text based on the original article at the MIMS and Nordic EMBL Partnership websites.